Influence of a new oral contraceptive with drospirenone on lipid metabolism

Gynecological Endocrinology

Volumn 23, Issue 6, 2007, Pages 347-350

  Taneepanichskul, Surasak ^a   Phupong, Vorapong ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Drospirenone; High density lipoprotein cholesterol; Lipid metabolism; Low density lipoprotein cholesterol; Oral contraception

Indexed keywords

CHOLESTEROL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART PROTECTION; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MULTIPLE CYCLE TREATMENT; NORMAL HUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANDROSTENES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; LIPID METABOLISM; TRIGLYCERIDES;

EID: 34447132119     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590701325731     Document Type: Article

References (19)

1. Skouby SO. The rationale for a wider range of progestogens. Climacteric 2000;3(Suppl 2):14-20.
2. Burkman RT. Lipid metabolism effects with desogestrel-containing oral contraceptives. Am J Obstet Gynecol 1993;168:1033-1040.
3. Hedon B. The evolution of oral contraceptives. Maximizing efficacy, minimizing risks. Acta Obstet Gynecol Scand Suppl 1990;152:7-12.
4. Krauss RM, Burkman RT Jr. The metabolic impact of oral contraceptives. Am J Obstet Gynecol 1992;167:1177-1184.
5. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38.
6. Foidart JM. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care 2000;5(Suppl 3):25-33.
7. Oelkers W. Drospirenone - a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care 2000;5(Suppl 3):17-24.
8. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000;61:105-111.
9. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-1821.
10. Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 2004;69:271-278.
11. World Health Organization. Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use methods. Geneva: World Health Organization; 1996.
12. Crook D, Godsland I. Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism. Contraception 1998;57:189-201.
13. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002;161:1-16.
14. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005;71:409-416.
15. Jacobs DR Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990;131:32-47.
16. Crook D, Godsland IF, Worthington M, Felton CV, Proudler AJ, Stevenson JC. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins. Am J Obstet Gynecol 1993;169:1183-1189.
17. Teichmann A. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. Int J Fertil Menopausal Stud 1995;40(Suppl 2):98-104.
18. Wiegratz I, Jung-Hoffmann C, Gross W, Kuhl H. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Contraception 1998;58:83-91.
19. NIH Consensus conference. Triglyceride, high-density lipoprotein, and coronary heart disease. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. J Am Med Assoc 1993;269:505-510.